1 BACKGROUND: Despite current preventive strategies, bacterial contamination of platelets is the highest residual infectious risk in transfusion. Bacteria can grow from an initial concentration of 0.03-0.3 colony-forming units (CFUs)/mL up to 10 8 to 10 9 CFUs/mL over the product shelf life. The aim of this study was to develop a cost-effective approach for an early, rapid, sensitive, and generic detection of bacteria in platelet concentrates.
STUDY DESIGN AND METHODS:
A large panel of bacteria involved in transfusion reactions, including clinical isolates and reference strains, was established. Sampling was performed 24 hours after platelet spiking. After an optimized culture step for increasing bacterial growth, a microbead-based immunoassay allowed the generic detection of bacteria. Antibody production and immunoassay development took place exclusively with bacteria spiked in fresh platelet concentrates to improve the specificity of the test.
RESULTS:
Antibodies for the generic detection of either gram-negative or gram-positive bacteria were selected for the microbead-based immunoassay. Our approach, combining the improved culture step with the immunoassay, allowed sensitive detection of 1 to 10 CFUs/mL for gram-negative and 1 to 10 2 CFUs/mL for gram-positive species.
CONCLUSION:
In this study, a new approach combining bacterial culture with immunoassay was developed for the generic and sensitive detection of bacteria in platelet concentrates. This efficient and easily automatable approach allows tested platelets to be used on Day 2 after collection and could represent an alternative strategy for reducing the risk of transfusiontransmitted bacterial infections. This strategy could be adapted for the detection of bacteria in other cellular products.
P revention of transfusion-transmitted infections is one of the major goals in transfusion medicine. The residual risk of transmitting the major viruses hepatitis C virus, hepatitis B virus, and human immunodeficiency virus has been reduced to a minimum using nucleic amplification technologies and fourth-generation serology screening tests. 1 In the period 2010 to 2013, among the 96,798,000 blood components distributed, the European commission reported 111 transfusion-transmitted infections in the European Union, including 73 bacterial (66%), 35 viral (32%), and 3 parasitic cases (<3%). 2 Bacterial contamination remains the highest residual infectious risk despite current preventive strategies. 1 Bacterial detection methods have been developed to limit the transfusion of bacterially contaminated platelets. Currently, none of the evaluated methods have been able to fulfill the specifications of a perfect test, which should have a high detection sensitivity and specificity and be reliable and rapid with a low cost. 3 Many countries have implemented automated culture methods for bacterial screening. Products are tested with continuous monitoring and are distributed as "negative-to-date" based on the status of the culture at the time the unit is released. [4] [5] [6] As an alternative option, rapid bacterial detection systems with a testing time reduced to 1 to 3 hours have been developed. 1 Some of these systems, based on the fluorescence-activated cell sorting method, 7 nucleic acid testing within the ribosomal bacterial genes, or portable assays, have been reported by several groups. However, the detection methods implemented in recent years have reduced the number of transfusions of bacterially contaminated blood products without eliminating this risk.
A large diversity of species is found in contaminated platelets, which represents a key challenge for the development of a generic bacterial detection test. Contamination of platelets with gram-negative organisms, although less common than gram-positive organisms, is more likely to result in clinically significant reactions. 1, 5, 8 Moreover, the immune status of the recipient will determine the level of severity of the reaction, which can range from minor symptoms to lifethreatening sepsis or even death. The majority of transfusion reactions caused by bacterial contamination of platelet concentrates occur following transfusion of 3-to 5-day-old units. However, in 2015 a fatal case was reported in France following transfusion of a 2-day-old platelet concentrate contaminated with the Enterobacteriaceae Citrobacter koseri.
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In this study, we developed a cost-effective and easyto-use approach for the early, rapid, sensitive, and generic detection of bacteria in platelet concentrates. Our attention was focused on an easily automatable technique able to deliver definitive results on Day 2 after collection. First, we implemented a simple optimized culture step to increase the bacterial concentration in the platelet concentrate sample. Second, development of the immunoassay required paying particular attention to the production and selection of antibodies directed against bacteria implicated in transfusion issues. A major concern was the adaptability of the process developed here for use in blood transfusion services.
MATERIALS AND METHODS

Bacterial strains
A large panel of bacteria involved in transfusion reactions, including clinical isolates and reference strains, was established. All bacteria used in this study had previously been characterized with regard to their ability to grow in 15-mL platelet concentrate samples, in the usual storage conditions of platelets units.
Strains The selection of the following four strains was based on their provision in the first international repository for transfusion-relevant bacteria (transfusion-relevant bacteria reference strains [TRBRSs): E. coli PEI-B-P-19, K. pneumoniae PEI-B-P-08, S. epidermidis PEI-B-P-06, and Streptococcus pyogenes PEI-B-P-20. 10 The TRBRS were obtained from the Paul Ehrlich Institute (PEI). In this proof-of-concept study, each of the four TRBRS strains were used in a deviant way to the information for use provided from the PEI, as they were grown on agar plates to be cryopreserved rather than used immediately for spiking. All bacterial strains, including the four reference TRBRS strains, were grown on Mueller-Hinton agar plates (Bio-Rad Laboratories) for 24 hours at 37 C. Using a sterile loop, bacteria were transferred to 2-mL cryovials containing glass beads in a solution of 20% glycerol (Technical Service Consultants Ltd). Bacteria were cryopreserved at −80 C until use.
Platelet concentrates
Pooled platelets prepared from five whole blood donations by the buffy-coat pooling method were produced at the French Blood Service (EFS Occitanie Pyrénées-Méditerran-née), using an automated system (TACSI, Terumo BCT). All donors provided informed consent for platelets to be used for research purposes. On Day 0, whole blood units were collected with a quintuple bag (NPT6280LA Macopharma) and stored between 18 and 24 C. On Day 1, the whole blood units (467 AE 7 mL) were centrifuged at 4108g (Cryofuge 6000, Heraeus) for 18 minutes at 22 C. The centrifuged products were then separated with top-and-bottom separation on automatic presses (Macopress Smart, Macopharma). Five ABO isogroup buffy-coat units and 280 mL of platelet additive solutions (InterSol, Fenwal) were pooled using the integrated pooling system in the TACSI kit. Pools were then placed in the automatic device for centrifugation and leukoreduction. The mean platelet content under routine conditions for TACSI leukoreduced platelet concentrates is 4.5 AE 0.4 10 11 with a mean volume of 333 AE11 mL.
After preparation, platelets were stored between 20 and 24 C, with agitation.
Spiking of platelet concentrates
One inoculated cryobead was transferred to a Mueller-Hinton agar plate and moved around the surface before incubation for 24 hours at 37 C. Two colonies were then taken from the plate and added in 10 mL of trypticase soy broth (Bio-Rad Laboratories) and cultured at 37 C. Overnight trypticase soy broth cultures were diluted in phosphate buffered saline (PBS) (Life Technologies), and bacterial titers were determined by plating diluted suspensions in duplicate on Mueller-Hinton agar plates (Bio-Rad Laboratories).
Whole platelet concentrate units
Overnight trypticase soy broth bacterial cultures were serially diluted in sterile PBS to achieve a final concentration of approximately 10 CFU/mL. Using a sterile syringe, 10 mL of platelets were removed from the platelet concentrate unit via one of the bag tubings and conserved. The platelet concentrate unit was then inoculated with 1 mL of the bacterial dilution estimated at approximately 10 CFU/mL via the same tubing using a second sterile syringe. The 10 mL previously removed were then reinjected to allow the entire bacterial inoculum to pass through the tubing. The inoculated platelet concentrate units were mixed by inversion at 21 C on a platelet agitator at 60 rpm. We targeted a concentration below 1 CFU/mL in each platelet concentrate unit spiked. As this value is below the analytical limit of the quantitative plate method, these values were calculated based on the concentrations in the prepared inoculum.
Platelet concentrate tube models
Aliquots of 15 mL of platelet concentrate were aseptically spiked with 150 μL of bacterial cultures previously diluted at 1:100 in sterile PBS to achieve a bacterial concentration in platelets between 0.06 and 0.75 CFU/mL. Bacterial inocula were determined by agar plating. The spiked platelet concentrates were incubated at 21 C on a platelet agitator at 60 rpm for 24 to 48 hours to mimic the platelet concentrate storage conditions.
Preanalytical steps
The preanalytical steps are illustrated in Fig. 1 .
Bacterial growth enrichment
One aliquot of 16 mL of spiked platelet concentrate was sampled, vigorously vortexed, separated into two aliquots of 8 mL in 50 mL tubes (Falcon), and centrifuged for 10 minutes at 4000g. After supernatant elimination, the pellet was resuspended in each tube in 10 mL of brain-heart infusion broth and incubated for 6 or 9 hours at 37 C under agitation (120 rpm). Bacterial titers were determined by agar plating.
Lysis
After growth enrichment of the spiked platelet concentrate, 1 mL of each 50-mL tube was sampled and added to a 2-mL microtube, which was centrifuged at 5000g for 10 minutes. The two pellets were resuspended in 100 μL of lysozyme buffer and incubated for 30 minutes at room temperature. Then, 100 μL of the lysis buffer (IQ-Check, Bio-Rad Laboratories) was added to each microtube, and the samples were incubated for 30 minutes at room temperature. Lysed bacteria were transferred in duplicates to a 96-well plate for detection by a microbead-based immunoassay.
Microbead-based immunoassay
Monoclonal antibodies were produced, selected, and finally grafted on magnetic microbeads for the generic capture of gram-negative and gram-positive bacteria. The analytical method is illustrated in Fig. 1 .
Monoclonal antibody production and selection
Bacterial immunogens for monoclonal antibody generation were prepared by heating a mix of several strains for 10 minutes at 95 C.
Experimental protocols requiring the use of mice were performed according to national regulations, and experiments were approved by the regional ethics committee of LanguedocRoussillon, France (authorization #CEEA-LR-0915-005).
As previously described in detail, 11 8-week-old CD1 mice were immunized with an intraperitoneal injection of a heated mix of 10 7 CFU bacteria mix emulsified in adjuvant (Ribi Adjuvant System, Sigma-Aldrich). Cells from the Sp2/0Ag14 myeloma cell line (ATCC, CRL 1581) were fused with splenocytes from selected immunized mice according to indirect enzymelinked immunosorbent assays, and the fusion product was plated in culture microplates for 15 days before primary screening. The screening steps were performed with bacterial strains spiked in platelet concentrates as well as on platelet concentrates without bacteria. This approach allowed removal of all false-positive clones and selection of clones detecting effectively lysed bacteria only. Antibody-producing hybridomas were identified and subcloned twice, then frozen in liquid nitrogen. Monoclonal antibodies were produced in vitro after collecting concentrated supernatants.
Magnetic microparticle coating
Tosyl-activated magnetic beads of 2.8 μm diameter (Dynabeads M-280, Invitrogen) were coated with 15 μg of monoclonal antibody per milligram of beads for 24 hours under gentle agitation. After blocking in Tris 100 mM 1% bovine serum albumin buffer, magnetic microparticles were washed three times in PBS -0.1% Tween 20-0.1% bovine serum albumin -0.03% Proclin and stored at 4 C until required for assays. These beads were used to capture lysed bacteria.
Immunoassay
To develop the immunoassay in a microplate format, streptavidin was coupled to antibodies using crosslinking reagents (succinimidyl 3-(2-pyridyldithio)propionate and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) (ThermoFisher Scientific), and peroxidase was biotinylated with pegylated biotinylation reagent (EZ-Link NHS-PEG12-Biotin, ThermoFisher Scientific). After washing in a 96-well plate with PBS -0.5%, Tween 20-0.03% Proclin (wash buffer), 500,000 magnetic beads coated with monoclonal antibodies were incubated in duplicate with 100 μL of lysed bacterial extracts at room temperature for 30 minutes under gentle agitation.
After three washes, streptavidin-conjugated monoclonal antibodies were incubated at 2 μg/mL with magnetic beads in PBS -0.1% Tween -0.1% bovine serum albumin -0.03% Proclin (reaction buffer) at room temperature for 30 minutes under gentle agitation. After three washes, biotinylated peroxidase was incubated at 2 μg/mL in the reaction buffer for 30 minutes. Beads were washed three times before being transferred to an enzyme-linked immunosorben assay microplate for reading (Maxisorp plate, Nunc). The HRP substrate (TMB solution, BioRad Laboratories) was added and incubated for 30 minutes (100 μL/well) at room temperature and the reaction was stopped with 50 μL/well of H 2 SO 4 4 N. Absorbance was read at 450 nm.
RESULTS
Preanalytical steps Spiking and sampling of whole platelet concentrate units
We performed spiking studies on whole platelet concentrate units to optimize sampling parameters. Five platelet concentrates were spiked with the four PEI TRBRSs and S. aureus ATCC 29213, with final concentrations of 0.1 CFU/mL. In accordance with Food and Drug Administration (FDA) recommendations, sampling occurred 24 hours after spiking. 12 Bacterial growth enrichment was first carried out on two initial aliquots of 8 mL of platelet concentrates. Growth of E. coli PEI and K. pneumoniae PEI occurred in both aliquots, whereas growth of S. epidermidis PEI occurred in one of the two aliquots, suggesting that 8-mL sampling was not enough for the detection of the slower-growing bacteria. Dissociation of S. aureus ATCC 29213 aggregates required a vigorous vortex step after sampling. Bacterial growth enrichment was then modified. The experiments were repeated on five new platelet concentrates. To summarize, 16 mL of spiked platelet concentrate was sampled, vigorously vortexed, and separated into two 8-mL aliquots before bacterial growth enrichment (Fig. 1) .
Bacterial growth enrichment
We measured the kinetics of bacterial growth in the whole platelet concentrate units spiked with a final bacterial concentration between 0.07 CFU/mL and 0.12 CFU/mL (T0) over 50 hours (Fig. 2) . Growth enrichment was performed on two aliquots of 8 mL (T0 + 24 h) and resulted in a substantial increase in the bacterial load for the five strains tested compared to the growth observed in the whole platelet concentrate unit. After 6 hours of enrichment (T0 + 30 h), the mean value of the bacterial loads, calculated using the plating method in the two aliquots, was between 2 and 3 log higher than in the whole spiked platelet concentrate. With 9 hours of enrichment (T0 + 33 h), this value varied from 2 to 5 log (Fig. 2) .
Subsequently, due to the restricted access to whole blood platelets for research studies, we used a platelet concentrate tube model (described in Materials and Methods) to test the bacterial growth in platelet concentrates of different bacteria involved in transfusional events. A larger panel of 18 gram-negative and 13 gram-positive bacteria was used to study bacterial growth after 6 hours or 9 hours of enrichment in samples from platelet concentrates spiked, using the platelet concentrate tube model, with a bacterial concentration between 0.06 CFU/mL and 0.75 CFU/mL. After 6 hours of enrichment, the bacterial concentration of gramnegative bacteria increased by between 3 and 5 log. A 9-hour enrichment resulted in an increase in the bacterial concentration of between 4 and 8 log (Fig. S1 , available as supporting information in the online version of this paper). For gram-positive bacteria, a 6-h enrichment resulted in an increase in the bacterial concentration of up to 5 log. After The bacterial concentrations were calculated using the quantitative plating method. The mean value of the two enriched samples was indicated and compared with the bacterial concentration calculated in the whole spiked platelet concentrate.
9 hours of enrichment, bacterial concentration increased by between 4 and 9 log (Fig. S1 , available as supporting information in the online version of this paper). We therefore selected the preanalytical step with 9 hours of enrichment.
Immunoassay
Antibody selection
Immunization protocols conducted to produce monoclonal antibodies directed against gram-negative bacteria allowed the selection of 458 hybridomas of interest. After subcloning, 56 purified clones were conserved. Screening of positive clones on individual bacterial strains cultured in platelet medium allowed selection of monoclonal antibodies with a generic detection profile. Table 1 presents the most relevant antibodies. The immunization strategy using a mix of gramnegative antigens from different bacterial species resulted in the production of three immunoglobulin M antibodies of interest. Using the immunization strategy with a mix of strains from unique bacterial species, the majority of antibodies obtained were immunoglobulin G antibodies. For this study, immunoglobulin G antibodies were favored as their purification is more convenient than purification of immunoglobulin M antibodies. First, we selected the antibody pair 9C12 / 16D12, able to detect targeted enterobacteria species (E. coli, S. marcescens, K. pneumoniae, and K. oxytoca). To increase the panreactivity of our test, we also selected the antibody 7C5, directed against A. baumannii species, and the antibody 16A4, directed against P. aeruginosa species.
Immunization protocols conducted to produce monoclonal antibodies directed against gram-positive bacteria allowed the selection of 180 hybridomas of interest. After subcloning, 45 purified clones were conserved. Again, screening of positive clones on individual bacterial strains cultured in platelet medium allowed selection of monoclonal antibodies with a generic detection profile. Table 2 presents the most relevant antibodies. We selected the antibody pair 24D9 / 31G10, which was able to detect the largest number of targeted species.
Bead-based immunoassay
Magnetic beads were tricoated with the gram-negative antibodies (9C12, 7C5, and 16A4). The detection of captured bacteria occurred with a mix of the three following antibodies conjugated with streptavidin: 16D12, 7C5, and 16A4. The gram-positive immunoassay design utilized a capture bead coated with the antibody 24D9, and detection step used the antibody 31G10 conjugated with streptavidin. Table 3 details the sensitivities of this bead-based immunoassay, ranging from 10 3 to 10 5 CFU/mL for gram-negative bacteria and from 10 5 to 10 7 CFU/mL for gram-positive species.
Preanalytical steps combined with immunoassay
To reach a higher sensitivity of detection, we combined the preanalytical steps of 9-hour enrichment of bacterial growth with the microbead-based immunoassay. All the experiments were performed using the platelet concentrate tube model. As shown in Table 3 , most gram-negative strains could theoretically be detected with a sensitivity of less than 1 CFU/mL, with the exception of P. aeruginosa, which could theoretically be detected in a range of 1 to 10 CFU/mL. Gram-positive species could be detected at 1 to 100 CFU/ mL, depending on the strains (Table 3) . To validate this combined approach, platelet concentrates were spiked with E. coli, K. pneumoniae, S. epidermidis, and S. aureus. After a 9-hour growth enrichment step, each culture was lysed and analyzed using the microbead-based immunoassay. We performed the assay twice for each strain in two different experiments, with a detection rate of 100%. As the duration of the whole test is 12 hours, platelet concentrates with a 
NT NT NT NT +++ NT − * E. coli PEI-B-P-19, E. coli RDC 115, S. marcescens CIP 103235, K. pneumoniae PEI-B-P-08, K. pneumoniae RDC 1033, A. baumannii CIP 70.34, A. baumannii iA, P. aeruginosa CIP 76.110, P. aeruginosa ATCC 10145, P. aeruginosa iA. † E. coli PEI-B-P-19, K. pneumoniae PEI-B-P-08, S. marcescens CIP 103235. ‡ E. coli PEI-B-P-19, E. coli CIP 76.24, E. coli iC, E. coli RDC 115, E. coli RDC 485. § S. marcescens CIP 103235, S. marcescens iA, S. marcescens iB. k A. baumannii CIP 70.34, A. baumannii iA, A. baumannii iB, A. baumannii iC. ¶ P. aeruginosa CIP 76.110, P. aeruginosa ATCC 10145, P. aeruginosa iA, P. aeruginosa iB. NT = not tested; PC = platelet concentrate.
negative result for bacterial contamination can be released within 36 hours, that is, Day 2 after donation.
DISCUSSION
Several strategies have been developed in the past 10 years to reduce the risk of transfusion-transmitted bacterial infections. While bacterial contamination may affect any blood component, the ambient temperature conditions required for storage of platelet concentrates are the most likely to facilitate bacterial growth. 13 Based on all the precautionary measures, the final platelet concentrate includes, in the worst-case scenario, a very limited number of viable bacteria, estimated to be 10 to 100 CFUs per bag, that is, 0.03-0.3 CFU/mL for a 300-mL platelet concentrate. 4, 14 In contrast to viruses, bacteria do multiply in blood components. 15 Indeed, bacteria can proliferate up to a concentration of 10 8 to 10 9 CFU/mL over the product shelf life. 4 Different strategies are in use to screen platelets before transfusion (Fig. 3) . The benefits of automated culture systems, such as BacT/ALERT (bioMérieux) or Bactec (Becton Dickinson), are their high analytical sensitivity (1-10 CFU/ mL), a complete bar-code-controlled system, and a fully automated process. 16 Sampling for culture methods should be performed at least 24 hours after donation, as a silent window exists in which bacteria are not detected in the sample. 14, 17 The disadvantages of these methods are the risk of sampling errors and false-negative results, despite the high sensitivity, especially for slow-growing bacteria and bacteria-forming aggregates in platelet concentrates. 6, 18, 19 Products tested by culture-based methods with continuous monitoring are distributed as "negative-to-date." Indeed, 30% to 50% of tested platelet concentrates are transfused before a positive signal occurs. 1, 3, 15, 16, 20 To overcome this issue, secondary rapid or culture testing using devices approved by the FDA is recommended on Days 4 and 5 after collection as a safety measure. 1, 12 However, this secondary testing is logistically complex and costly. 21 As an alternative to primary culture methods, rapid detection methods have been reported in a different concept (Fig. 3) . These methods which are currently CE or FDA licensed include the BactiFlow system (bioMérieux), which is a fluorescence-activated cell sorting method, 22 nucleic acid testing within the ribosomal bacterial genes, the PGD method (Verax) based on a lateral-flow immunoprecipitation of the bacterial cell-wall antigens, and the BacTx assay (Immunetics) that detects bacterial peptidoglycans. 1, 20, 21 The concept of the rapid detection methods concept includes the release of nontested platelets on Day 1 and Day 2 after blood donation and a sample collection on Day 3 or Day 4. testing method present the advantages of being sensitive automated systems. Turnaround times of 30 minutes and 60 minutes are required for the portable BacTx and Verax PGD assays respectively, but these assays have reduced sensitivities compared to automated methods. These tests can be set up in parallel, but the delay may prove incompatible for high-volume transfusion settings.
1,21
The only approach able to inactivate pathogens and therefore to reduce the risk of bacterial contaminations of blood products is the use of highly efficient pathogenreduction methods performed during the process of product preparation (Fig. 3) . 15, 23, 24 These technologies provide the opportunity to reduce the risk of septic transfusion reactions from bacterially contaminated platelet concentrates, but the disadvantages are their high costs and their limited effectiveness on spores and fast-growing bacteria. 20, [25] [26] [27] [28] [29] Moreover, pathogen-reduction technologies cannot be applied to products derived from cellular engineering. Bacterial contamination remains a significant challenge to blood safety. The addition of a short incubation step prior to a rapid test is a strategy previously mentioned in several publications. 14, 30, 31 The approach developed in this proofof-concept study combines a preanalytical culture step with a microbead-based immunoassay. To confirm the safety of the platelet concentrates, our objective was to enrich the bacterial load to 10 to 10 2 CFU/mL to ensure detection.
Spiking studies conducted on a large panel of bacteria with different growth kinetics allowed us to select the best preanalytical conditions. As recommended by the FDA, sampling was performed 24 hours after spiking. Based on culture method studies, 3, 4, 6, 14, 17 and to avoid false-negative results caused by the Poisson sampling errors, 14,17 16 mL of platelet concentrates were collected, vigorously vortexed, and separated into two aliquots before the bacterial culture step. The increase in the bacterial concentration observed after a 9-hour culture enrichment step was between 4 and 8 log for See also Fig. S1 , available as supporting information in the online version of this paper. LoD = limit of detection. gram-negative and between 4 and 9 log for gram-positive strains. We have not yet tested anaerobic strains in our conditions, as their clinical significance is not comparable to other strains able to reach significant levels in platelet concentrates. Stormer et al. 32 reported that Propionibacterium acnes lacks the capability to proliferate in platelet concentrates. The Australian Red Cross detected a component contaminated with Clostridium perfringens using only an aerobic culture method, suggesting that this organism may sometimes grow as a facultative aerobe. 17 Other obligate anaerobes are rarely detected. The production and the selection of generic monoclonal antibodies was a key challenge. In this context, we applied a dedicated strategy to consider the high bacterial diversity reported in contaminated platelet concentrate units. Moreover, the screening approach based on the selection of the sensitive (bacterial load) and specific (bacterial diversity) clones in highly stringent conditions took place in fresh platelet concentrates. This allowed the effective detection of bacteria in their biologic environment, an important point when considering the use of this process in clinical practice. The whole assay, combining a culture step and a bead-based immunoassay developed on a large panel of bacteria involved in transfusion reactions, allows sensitive detection of 1 to 10 CFU/mL for gram-negative and 1 to 10 2 CFU/mL for gram-positive species. Moreover, because results are available 36 hours after donation, platelet concentrates could be released on Day 2 with a negative test result for bacterial contamination (Fig. 3 ), in contrast with the negative-to-date concept of the automated culture methods currently employed in transfusion services. 3, 5 These preliminary results need to be confirmed in a second study on a large number of whole platelet concentrate units before to consider an industrial development of this analytical approach. This optimized detection approach could be used to prevent the bacterial risk observed for other cellular products, such as RBCs or biologic fluids. The use of magnetic microbeads coated with various antibodies improves the flexibility of the test. In this context, the microbiological safety of cell-based medicinal products, such as hematopoietic stem cell grafts, could be improved with innovative methods. Currently, culture methods are used to test their sterility according to the European and United States Pharmacopeias. For some advanced therapeutic medicinal products, 33 a rapid method for bacterial detection is necessary. Our analytical approach could be adapted at several steps of the process to anticipate decisions during the manufacturing process and to reduce both time and cost. In conclusion, our proof-of-concept study could represent an efficient strategy to deliver tested platelets on Day 2 after donation. The microbead-based immunoassay can be easily automated in a microplate format for the routine screening of hundreds of samples each day. Further developments could be applied in the near future to other biologic products to manage the risk of bacterial contamination.
